Sanaria featured in The New York Times, The Soul of a New Vaccine

The sign on the wall reads “Emergency Response Procedures for a Mosquito Release.”

Among them are “Do Not Leave the Room or Open Any Doors!!!” and “Do Not Panic!”

Everything in the room is white, including the lab coats and surgical masks — for sterility, yes, but also the better to see a mosquito. Hanging next to the sign, in vivid Coast Guard orange, is the last line of defense, a brace of fly swatters.

This room, the mosquito dissection lab, in an unassuming biotech park in the Washington suburbs, is at the heart of one of the most controversial |

In the latest Forbes' Wolfe Emerging Tech Report, Sanaria's new manufacturing facilities are featured as part of our efforts to develop a new vaccine against malaria.

Malaria vaccine plant takes a gamble

In a nondescript office park tucked between a hospital and a strip mall thrive hundreds of thousands of the most infectious malaria-carrying mosquitoes ever born. They will be dissected for the motherlode that they carry -- baby malaria parasites, fodder for a new malaria vaccine.

Sanaria, PATH Malaria Vaccine Initiative Open Manufacturing Facility For Producing World’s First “Whole-Parasite” Malaria Vaccine

Sanaria Inc. and the PATH Malaria Vaccine Initiative today officially opened a one-of-a-kind clinical manufacturing facility to produce a vaccine that uses a weakened form of the malaria parasite to fight a disease that annually kills more than one million people, most of them African children.

Sanaria Inc. Receives Multi-Year $3.47 Million U.S. NIH Phase I and Phase II Small Business Innovation Research Grants to Enhance Development of its Malaria Vaccine

Sanaria Inc., a Rockville, Maryland privately held company, announced the receipt of two multi-year Small Business Innovation Research (SBIR) Grants from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health. The grants will enhance the development of its whole parasite Malaria Vaccine. The Phase II grant is to establish multiple strains of the parasite that can be used to assess the effectiveness of Sanaria's Malaria Vaccine.

Bush recognizes social entrepreneurship

Like many such events, the recent White House Summit on malaria, which featured a speech and new grant announcements by Melinda Gates, was carefully choreographed with few surprises. But there was one.

President Bush began the closing keynote address by saying, “I want to thank those members of my Cabinet who are here, the ambassadors, the members of Congress, and I want to thank the social entrepreneurs who are with us today.” Bush then cited the Bill & Melinda Gates Foundation as “a fantastic example of social entrepreneurship, using business acumen to address social problems.”

Read more in the original |

Mosquito ‘factories’ to fight malaria

It's going to be fiddly work, but the saliva glands of mosquitoes are to be used as mini factories for churning out a novel vaccine against malaria. The vaccine is based on the whole parasite, rather than individual proteins, and may therefore work better than other vaccines in development because the body can mount a multi-pronged attack against it.

PATH Malaria Vaccine Initiative Announces New Partnership To Accelerate Development of Novel Malaria Vaccine Candidate MVI and Sanaria Inc. to Conduct Initial Safety and Test-of-Concept Trial

In a move that promises to expand the types of malaria vaccine candidates in clinical development, the PATH Malaria Vaccine Initiative (MVI) today announced a new partnership with Sanaria Inc., a Maryland company, to accelerate development of a unique malaria vaccine candidate.

Contact Us


We welcome your feedback and inquiries. Please be in touch.

Address:

Sanaria Inc.
9610 Medical Center Drive, Suite 200
Rockville, MD 20850

Phone:

+1.301.770.3222

Social: